on INNATE PHARMA (EPA:IPH)
Clarification on the status of SAR443579 treatment by Innate Pharma
Innate Pharma SA announced today that the abstract published on May 14, 2024 before the European Hematology Association congress is incorrect. Contrary to what is mentioned, the SAR443579/IPH6101 molecule has not received the status of “Breakthrough Designation”. It obtained “Fast Track” status from the FDA in June 2023.
Innate Pharma collaborates with Sanofi to develop multi-specific antibodies targeting NK cells. This cooperation includes the molecules SAR443579/IPH6101 and SAR445514/IPH6401. Innate Pharma could receive up to €400 million in milestone payments and royalties on net sales.
A second licensing agreement, concluded in December 2022, includes targets B7-H3 and others. This agreement could bring in up to 1.35 billion euros to Innate Pharma.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news